One patient who was detected a BRCA2-mutation had a durable clinical response for >4 years.[10] Cytotoxic T lymphocyte antigen 4 (CTLA-4), the programmed cell death protein-1/programmed death-ligand 1, and other immune checkpoint regulators have emerged as promising new targets for cancer therapeutics. This evidence concerns the gene PDCD1 and cancer.